Epigenetic mechanisms in mood disorders: Targeting neuroplasticity

Neuroscience

Volumn 264, Issue , 2014, Pages 112-130

  Fass, D M ^a,b   Schroeder, F A ^a   Perlis, R H ^a,b   Haggarty, S J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Chromatin; Epigenetics; Experimental medicine; Mood disorders; Neuroplasticity

Indexed keywords

AMITRIPTYLINE; BUTYRIC ACID; CARBAMAZEPINE; CLOZAPINE; DIZOCILPINE; ENTINOSTAT; FLUOXETINE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; IMIPRAMINE; LITHIUM SALT; PAROXETINE; ROMIDEPSIN; SULPIRIDE; TRANSCRIPTION FACTOR CLOCK; TRANYLCYPROMINE; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ACUTE STRESS; BIPOLAR DISORDER; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CHRONIC STRESS; DEPRESSION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC MARKER; GENETIC REGULATION; GENETIC VARIABILITY; HISTONE ACETYLATION; HUMAN; HUMAN GENOME; MAJOR DEPRESSION; MANIA; MOLECULAR MECHANICS; NERVE CELL; NERVE CELL PLASTICITY; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; TRANSCRIPTION REGULATION;

CHROMATIN; EPIGENETICS; EXPERIMENTAL MEDICINE; MOOD DISORDERS; NEUROPLASTICITY;

ANIMALS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; HUMANS; MICE; MOOD DISORDERS; NEURONAL PLASTICITY; RATS;

EID: 84895871392     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.01.041     Document Type: Review

References (142)

1. Abe N., Uchida S., Otsuki K., Hobara T., Yamagata H., Higuchi F., Shibata T., Watanabe Y. Altered sirtuin deacetylase gene expression in patients with a mood disorder. J Psychiatry Res 2011, 45:1106-1112.
2. Alarcon J.M., Malleret G., Touzani K., Vronskaya S., Ishii S., Kandel E.R., Barco A. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice. a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 2004, 42:947-959.
3. Appel S.H. Effect of inhibition of RNA synthesis on neural information storage. Nature 1965, 207:1163-1166.
4. Arent C.O., Valvassori S.S., Fries G.R., Stertz L., Ferreira C.L., Lopes-Borges J., Mariot E., Varela R.B., Ornell F., Kapczinski F., Andersen M.L., Quevedo J. Neuroanatomical profile of antimaniac effects of histone deacetylases inhibitors. Mol Neurobiol 2011, 43:207-214.
5. Arey R., McClung C.A. An inhibitor of casein kinase 1 epsilon/delta partially normalizes the manic-like behaviors of the ClockDelta19 mouse. Behav Pharmacol 2012, 23:392-396.
6. Baune B.T., Miller R., McAfoose J., Johnson M., Quirk F., Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res 2010, 176:183-189.
7. Beconi M., Aziz O., Matthews K., Moumne L., O'Connell C., Yates D., Clifton S., Pett H., Vann J., Crowley L., Haughan A.F., Smith D.L., Woodman B., Bates G.P., Brookfield F., Burli R.W., McAllister L., Dominguez G., Munoz-Sanjuan I., Beaumont V. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. PLoS One 2012, 7:e44498.
8. Berndsen C.E., Denu J.M. Catalysis and substrate selection by histone/protein lysine acetyltransferases. Curr Opin Struct Biol 2008, 18:682-689.
9. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
10. Bieliauskas A.V., Pflum M.K. Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 2008, 37:1402-1413.
11. Borrelli E., Nestler E.J., Allis C.D., Sassone-Corsi P. Decoding the epigenetic language of neuronal plasticity. Neuron 2008, 60:961-974.
12. Bowden C.L., Perlis R.H., Thase M.E., Ketter T.A., Ostacher M.M., Calabrese J.R., Reilly-Harrington N.A., Gonzalez J.M., Singh V., Nierenberg A.A., Sachs G.S. Aims and results of the NIMH systematic treatment enhancement program for bipolar disorder (STEP-BD). CNS Neurosci Ther 2012, 18:243-249.
13. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., Mazitschek R. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010, 6:238-243.
14. Brennand K.J., Gage F.H. Concise review: the promise of human induced pluripotent stem cell-based studies of schizophrenia. Stem Cells 2011, 29:1915-1922.
15. Brown S.A., Kowalska E., Dallmann R. (Re)inventing the circadian feedback loop. Dev Cell 2012, 22:477-487.
16. Calabrese J.R., Huffman R.F., White R.L., Edwards S., Thompson T.R., Ascher J.A., Monaghan E.T., Leadbetter R.A. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008, 10:323-333.
17. Chandramohan Y., Droste S.K., Arthur J.S., Reul J.M. The forced swimming-induced behavioural immobility response involves histone H3 phospho-acetylation and c-Fos induction in dentate gyrus granule neurons via activation of the N-methyl-d-aspartate/extracellular signal-regulated kinase/mitogen- and stress-activated kinase signalling pathway. Eur J Neurosci 2008, 27:2701-2713.
18. Cheung A.Y., Horvath L.M., Carrel L., Ellis J. X-chromosome inactivation in rett syndrome human induced pluripotent stem cells. Front Psychiatry 2012, 3:24.
19. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
20. Costa E., Dong E., Grayson D.R., Ruzicka W.B., Simonini M.V., Veldic M., Guidotti A. Epigenetic targets in GABAergic neurons to treat schizophrenia. Adv Pharmacol 2006, 54:95-117.
21. Costa E., Grayson D.R., Guidotti A. Epigenetic downregulation of GABAergic function in schizophrenia: potential for pharmacological intervention?. Mol Interv 2003, 3:220-229.
22. Covington H.E., Maze I., LaPlant Q.C., Vialou V.F., Ohnishi Y.N., Berton O., Fass D.M., Renthal W., Rush A.J., Wu E.Y., Ghose S., Krishnan V., Russo S.J., Tamminga C., Haggarty S.J., Nestler E.J. Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009, 29:11451-11460.
23. Covington H.E., Maze I., Sun H., Bomze H.M., DeMaio K.D., Wu E.Y., Lobo M.K., Ghose S., Krishnan V., Mouzon E., Neve R.L., Tamminga C.A., Nestler E.J. A role for repressive histone methylation in cocaine-induced vulnerability to stress. Neuron 2011, 71:656-670.
24. Covington H.E., Vialou V., Nestler E.J. From synapse to nucleus: novel targets for treating depression. Neuropharmacology 2010, 58:683-693.
25. Day J.J., Sweatt J.D. Epigenetic mechanisms in cognition. Neuron 2011, 70:813-829.
26. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., Van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003, 370:737-749.
27. Derrien T., Johnson R., Bussotti G., Tanzer A., Djebali S., Tilgner H., Guernec G., Martin D., Merkel A., Knowles D.G., Lagarde J., Veeravalli L., Ruan X., Ruan Y., Lassmann T., Carninci P., Brown J.B., Lipovich L., Gonzalez J.M., Thomas M., Davis C.A., Shiekhattar R., Gingeras T.R., Hubbard T.J., Notredame C., Harrow J., Guigo R. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012, 22:1775-1789.
28. Dierckx B., Heijnen W.T., van den Broek W.W., Birkenhager T.K. Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a meta-analysis. Bipolar Disord 2012, 14:146-150.
29. DiTacchio L., Le H.D., Vollmers C., Hatori M., Witcher M., Secombe J., Panda S. Histone lysine demethylase JARID1a activates CLOCK-BMAL1 and influences the circadian clock. Science 2011, 333:1881-1885.
30. Doi M., Hirayama J., Sassone-Corsi P. Circadian regulator CLOCK is a histone acetyltransferase. Cell 2006, 125:497-508.
31. Dong E., Agis-Balboa R.C., Simonini M.V., Grayson D.R., Costa E., Guidotti A. Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc Natl Acad Sci U S A 2005, 102:12578-12583.
32. Dong S., Rogan S.C., Roth B.L. Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs. Nat Protoc 2010, 5:561-573.
33. Duong H.A., Robles M.S., Knutti D., Weitz C.J. A molecular mechanism for circadian clock negative feedback. Science 2011, 332:1436-1439.
34. Espallergues J., Teegarden S.L., Veerakumar A., Boulden J., Challis C., Jochems J., Chan M., Petersen T., Deneris E., Matthias P., Hahn C.G., Lucki I., Beck S.G., Berton O. HDAC6 regulates glucocorticoid receptor signaling in serotonin pathways with critical impact on stress resilience. J Neurosci 2012, 32:4400-4416.
35. Etchegaray J.P., Yang X., DeBruyne J.P., Peters A.H., Weaver D.R., Jenuwein T., Reppert S.M. The polycomb group protein EZH2 is required for mammalian circadian clock function. J Biol Chem 2006, 281:21209-21215.
36. Farra N., Zhang W.B., Pasceri P., Eubanks J.H., Salter M.W., Ellis J. Rett syndrome induced pluripotent stem cell-derived neurons reveal novel neurophysiological alterations. Mol Psychiatry 2012.
37. Fass D.M., Reis S.A., Ghosh B., Hennig K.M., Joseph N.F., Zhao W.N., Nieland T.J., Guan J.S., Groves Kuhnle C.E., Tang W., Barker D.D., Mazitschek R., Schreiber S.L., Tsai L.H., Haggarty S.J. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology 2013, 64:81-96.
38. Fass D.M., Shah R., Ghosh B., Hennig K., Norton S., Zhao W.N., Reis S.A., Klein P.S., Mazitschek R., Maglathlin R.L., Lewis T.A., Haggarty S.J. Effect of inhibiting histone deacetylase with short-chain carboxylic acids and their hydroxamic acid analogs on vertebrate development and neuronal chromatin. ACS Med Chem Lett 2010, 2:39-42.
39. Fenno L., Yizhar O., Deisseroth K. The development and application of optogenetics. Annu Rev Neurosci 2011, 34:389-412.
40. Filippakopoulos P., Knapp S. The bromodomain interaction module. FEBS Lett 2012, 586:2692-2704.
41. Fischer A., Sananbenesi F., Wang X., Dobbin M., Tsai L.H. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007, 447:178-182.
42. Fischle W., Dequiedt F., Hendzel M.J., Guenther M.G., Lazar M.A., Voelter W., Verdin E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002, 9:45-57.
43. Fukada M., Hanai A., Nakayama A., Suzuki T., Miyata N., Rodriguiz R.M., Wetsel W.C., Yao T.P., Kawaguchi Y. Loss of deacetylation activity of Hdac6 affects emotional behavior in mice. PLoS One 2012, 7:e30924.
44. Gamazon E.R., Badner J.A., Cheng L., Zhang C., Zhang D., Cox N.J., Gershon E.S., Kelsoe J.R., Greenwood T.A., Nievergelt C.M., Chen C., McKinney R., Shilling P.D., Schork N.J., Smith E.N., Bloss C.S., Nurnberger J.I., Edenberg H.J., Foroud T., Koller D.L., Scheftner W.A., Coryell W., Rice J., Lawson W.B., Nwulia E.A., Hipolito M., Byerley W., McMahon F.J., Schulze T.G., Berrettini W.H., Potash J.B., Zandi P.P., Mahon P.B., McInnis M.G., Zollner S., Zhang P., Craig D.W., Szelinger S., Barrett T.B., Liu C. Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants. Mol Psychiatry 2012, [Epub ahead of print]. 10.1038/mp.2011.174.
45. Gardner K.E., Allis C.D., Strahl B.D. Operating on chromatin, a colorful language where context matters. J Mol Biol 2011, 409:36-46.
46. Gavin D.P., Kartan S., Chase K., Jayaraman S., Sharma R.P. Histone deacetylase inhibitors and candidate gene expression: an in vivo and in vitro approach to studying chromatin remodeling in a clinical population. J Psychiatr Res 2009, 43:870-876.
47. Gekakis N., Staknis D., Nguyen H.B., Davis F.C., Wilsbacher L.D., King D.P., Jayaraman S., Weitz C.J. Role of the CLOCK protein in the mammalian circadian mechanism. Science 1998, 280:1564-1569.
48. Gertz J., Varley K.E., Reddy T.E., Bowling K.M., Pauli F., Parker S.L., Kucera K.S., Willard H.F., Myers R.M. Analysis of DNA methylation in a three-generation family reveals widespread genetic influence on epigenetic regulation. PLoS Genet 2011, 7:e1002228.
49. Graff J., Rei D., Guan J.S., Wang W.Y., Seo J., Hennig K.M., Nieland T.J., Fass D.M., Kao P.F., Kahn M., Su S.C., Samiei A., Joseph N., Haggarty S.J., Delalle I., Tsai L.H. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483:222-226.
50. Greenberg P.E., Stiglin L.E., Finkelstein S.N., Berndt E.R. The economic burden of depression in 1990. J Clin Psychiatry 1993, 54:405-418.
51. Grskovic M., Javaherian A., Strulovici B., Daley G.Q. Induced pluripotent stem cells - opportunities for disease modelling and drug discovery. Nat Rev Drug Discov 2011, 10:915-929.
52. Guan J.S., Haggarty S.J., Giacometti E., Dannenberg J.H., Joseph N., Gao J., Nieland T.J., Zhou Y., Wang X., Mazitschek R., Bradner J.E., DePinho R.A., Jaenisch R., Tsai L.H. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009, 459:55-60.
53. Guan Z., Giustetto M., Lomvardas S., Kim J.H., Miniaci M.C., Schwartz J.H., Thanos D., Kandel E.R. Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 2002, 111:483-493.
54. Guidotti A., Auta J., Chen Y., Davis J.M., Dong E., Gavin D.P., Grayson D.R., Matrisciano F., Pinna G., Satta R., Sharma R.P., Tremolizzo L., Tueting P. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 2011, 60:1007-1016.
55. Gundersen B.B., Blendy J.A. Effects of the histone deacetylase inhibitor sodium butyrate in models of depression and anxiety. Neuropharmacology 2009, 57:67-74.
56. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145:423-434.
57. Haggarty S.J., Tsai L.H. Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiol Learn Mem 2011, 96:41-52.
58. Higuchi F., Uchida S., Yamagata H., Otsuki K., Hobara T., Abe N., Shibata T., Watanabe Y. State-dependent changes in the expression of DNA methyltransferases in mood disorder patients. J Psychiatry Res 2011, 45:1295-1300.
59. Hirayama J., Sahar S., Grimaldi B., Tamaru T., Takamatsu K., Nakahata Y., Sassone-Corsi P. CLOCK-mediated acetylation of BMAL1 controls circadian function. Nature 2007, 450:1086-1090.
60. Hirschfeld R.A., Bowden C.L., Gitlin M.J., Keck P.E., Perlis R.H., Suppes T., Thase M.E. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159:12.
61. Hobara T., Uchida S., Otsuki K., Matsubara T., Funato H., Matsuo K., Suetsugi M., Watanabe Y. Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatry Res 2010, 44:263-270.
62. Hollis F., Duclot F., Gunjan A., Kabbaj M. Individual differences in the effect of social defeat on anhedonia and histone acetylation in the rat hippocampus. Horm Behav 2011, 59:331-337.
63. Houston I., Peter C.J., Mitchell A., Straubhaar J., Rogaev E., Akbarian S. Epigenetics in the human brain. Neuropsychopharmacology 2013, 38:183-197.
64. Hunter R.G., McCarthy K.J., Milne T.A., Pfaff D.W., McEwen B.S. Regulation of hippocampal H3 histone methylation by acute and chronic stress. Proc Natl Acad Sci U S A 2009, 106:20912-20917.
65. Husain M.M., Rush A.J., Wisniewski S.R., McClintock S.M., Fava M., Nierenberg A.A., Davis L., Balasubramani G.K., Young E., Albala A.A., Trivedi M.H. Family history of depression and therapeutic outcome: findings from STAR*D. J Clin Psychiatry 2009, 70:185-195.
66. Iga J., Ueno S., Yamauchi K., Numata S., Kinouchi S., Tayoshi-Shibuya S., Song H., Ohmori T. Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:628-632.
67. Jakobsson J., Cordero M.I., Bisaz R., Groner A.C., Busskamp V., Bensadoun J.C., Cammas F., Losson R., Mansuy I.M., Sandi C., Trono D. KAP1-mediated epigenetic repression in the forebrain modulates behavioral vulnerability to stress. Neuron 2008, 60:818-831.
68. Johansson A.S., Brask J., Owe-Larsson B., Hetta J., Lundkvist G.B. Valproic acid phase shifts the rhythmic expression of Period2::Luciferase. J Biol Rhythms 2011, 26:541-551.
69. Judd L.L., Akiskal H.S., Schettler P.J., Coryell W., Endicott J., Maser J.D., Solomon D.A., Leon A.C., Keller M.B. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003, 60:261-269.
70. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., Leon A.C., Rice J.A., Keller M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002, 59:530-537.
71. Katada S., Sassone-Corsi P. The histone methyltransferase MLL1 permits the oscillation of circadian gene expression. Nat Struct Mol Biol 2010, 17:1414-1421.
72. Keck P.E., Perlis R.H., Otto M.W., Carpenter D., Ross R., Docherty J.P. Expert consensus guideline series: treatment of bipolar disorder 2004. Postgrad Med 2004, 1-120.
73. Kim W.Y., Kim S., Kim H. Chronic microinjection of valproic acid into the nucleus accumbens attenuates amphetamine-induced locomotor activity. Neurosci Lett 2008, 432:54-57.
74. King D.P., Zhao Y., Sangoram A.M., Wilsbacher L.D., Tanaka M., Antoch M.P., Steeves T.D., Vitaterna M.H., Kornhauser J.M., Lowrey P.L., Turek F.W., Takahashi J.S. Positional cloning of the mouse circadian clock gene. Cell 1997, 89:641-653.
75. Korzus E., Rosenfeld M.G., Mayford M. CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 2004, 42:961-972.
76. Kozikowski A.P., Gunosewoyo H., Guo S., Gaisina I.N., Walter R.L., Ketcherside A., McClung C.A., Mesecar A.D., Caldarone B. Identification of a glycogen synthase kinase-3beta inhibitor that attenuates hyperactivity in CLOCK mutant mice. ChemMedChem 2011, 6:1593-1602.
77. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
78. Kundakovic M., Chen Y., Guidotti A., Grayson D.R. The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. Mol Pharmacol 2009, 75:342-354.
79. Kurita M., Holloway T., Garcia-Bea A., Kozlenkov A., Friedman A.K., Moreno J.L., Heshmati M., Golden S.A., Kennedy P.J., Takahashi N., Dietz D.M., Mocci G., Gabilondo A.M., Hanks J., Umali A., Callado L.F., Gallitano A.L., Neve R.L., Shen L., Buxbaum J.D., Han M.H., Nestler E.J., Meana J.J., Russo S.J., Gonzalez-Maeso J. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 2012, 15:1245-1254.
80. Lee M.G., Wynder C., Schmidt D.M., McCafferty D.G., Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 2006, 13:563-567.
81. Levenson J.M., O'Riordan K.J., Brown K.D., Trinh M.A., Molfese D.L., Sweatt J.D. Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem 2004, 279:40545-40559.
82. Levenson J.M., Sweatt J.D. Epigenetic mechanisms in memory formation. Nat Rev Neurosci 2005, 6:108-118.
83. Lin M., Pedrosa E., Shah A., Hrabovsky A., Maqbool S., Zheng D., Lachman H.M. RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. PLoS One 2011, 6:e23356.
84. Manji H.K., Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001, 35:5-49.
85. Marcaurelle L.A., Comer E., Dandapani S., Duvall J.R., Gerard B., Kesavan S., Lee M.Dt., Liu H., Lowe J.T., Marie J.C., Mulrooney C.A., Pandya B.A., Rowley A., Ryba T.D., Suh B.C., Wei J., Young D.W., Akella L.B., Ross N.T., Zhang Y.L., Fass D.M., Reis S.A., Zhao W.N., Haggarty S.J., Palmer M., Foley M.A. An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. J Am Chem Soc 2010, 132:16962-16976.
86. McQuown S.C., Barrett R.M., Matheos D.P., Post R.J., Rogge G.A., Alenghat T., Mullican S.E., Jones S., Rusche J.R., Lazar M.A., Wood M.A. HDAC3 is a critical negative regulator of long-term memory formation. J Neurosci 2011, 31:764-774.
87. Mikaelsson M.A., Miller C.A. DNA methylation: a transcriptional mechanism co-opted by the developed mammalian brain?. Epigenetics 2011, 6:548-551.
88. Milhiet V., Etain B., Boudebesse C., Bellivier F. Circadian biomarkers, circadian genes and bipolar disorders. J Physiol Paris 2011, 105:183-189.
89. Murrough J.W., Charney D.S. Is there anything really novel on the antidepressant horizon?. Curr Psychiatry Rep 2012, 14(6):643-649.
90. Nakahata Y., Kaluzova M., Grimaldi B., Sahar S., Hirayama J., Chen D., Guarente L.P., Sassone-Corsi P. The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 2008, 134:329-340.
91. Neelamegam R., Ricq E.L., Malvaez M., Patnaik D., Norton S., Carlin S.M., Hill I.T., Wood M.A., Haggarty S.J., Hooker J.M. Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS Chem Neurosci 2012, 3:120-128.
92. Nemeroff C.B., Evans D.L., Gyulai L., Sachs G.S., Bowden C.L., Gergel I.P., Oakes R., Pitts C.D. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001, 158:906-912.
93. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl. 1):1-93.
94. Nguyen P.V., Abel T., Kandel E.R. Requirement of a critical period of transcription for induction of a late phase of LTP. Science 1994, 265:1104-1107.
95. Okita K., Yamanaka S. Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci 2011, 366:2198-2207.
96. Osby U., Brandt L., Correia N., Ekbom A., Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001, 58:844-850.
97. Pedrosa E., Sandler V., Shah A., Carroll R., Chang C., Rockowitz S., Guo X., Zheng D., Lachman H.M. Development of patient-specific neurons in schizophrenia using induced pluripotent stem cells. J Neurogenet 2011, 25:88-103.
98. Perlis R.H., Ostacher M.J., Patel J.K., Marangell L.B., Zhang H., Wisniewski S.R., Ketter T.A., Miklowitz D.J., Otto M.W., Gyulai L., Reilly-Harrington N.A., Nierenberg A.A., Sachs G.S., Thase M.E. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006, 163:217-224.
99. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734-36741.
100. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
101. Quiroz J.A., Manji H.K. Enhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders. Dialogues Clin Neurosci 2002, 4:73-92.
102. Racki L.R., Narlikar G.J. ATP-dependent chromatin remodeling enzymes: two heads are not better, just different. Curr Opin Genet Dev 2008, 18:137-144.
103. Rinn J.L., Chang H.Y. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012, 81:145-166.
104. Roybal K., Theobold D., Graham A., DiNieri J.A., Russo S.J., Krishnan V., Chakravarty S., Peevey J., Oehrlein N., Birnbaum S., Vitaterna M.H., Orsulak P., Takahashi J.S., Nestler E.J., Carlezon W.A., McClung C.A. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A 2007, 104:6406-6411.
105. Rush A.J., Warden D., Wisniewski S.R., Fava M., Trivedi M.H., Gaynes B.N., Nierenberg A.A. STAR*D: revising conventional wisdom. CNS Drugs 2009, 23:627-647.
106. Rush A.J., Wisniewski S.R., Warden D., Luther J.F., Davis L.L., Fava M., Nierenberg A.A., Trivedi M.H. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008, 65:870-880.
107. Ruthenburg A.J., Li H., Patel D.J., Allis C.D. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 2007, 8:983-994.
108. Ruzicka W.B., Zhubi A., Veldic M., Grayson D.R., Costa E., Guidotti A. Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. Mol Psychiatry 2007, 12:385-397.
109. Sachs G.S., Nierenberg A.A., Calabrese J.R., Marangell L.B., Wisniewski S.R., Gyulai L., Friedman E.S., Bowden C.L., Fossey M.D., Ostacher M.J., Ketter T.A., Patel J., Hauser P., Rapport D., Martinez J.M., Allen M.H., Miklowitz D.J., Otto M.W., Dennehy E.B., Thase M.E. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007, 356:1711-1722.
110. Scherk H., Pajonk F.G., Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007, 64:442-455.
111. Schroeder F.A., Lin C.L., Crusio W.E., Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 2007, 62:55-64.
112. Selvi B.R., Cassel J.C., Kundu T.K., Boutillier A.L. Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases. Biochim Biophys Acta 2010, 1799:840-853.
113. Sharma R.P., Rosen C., Kartan S., Guidotti A., Costa E., Grayson D.R., Chase K. Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population. Schizophr Res 2006, 88:227-231.
114. Sheridan S.D., Theriault K.M., Reis S.A., Zhou F., Madison J.M., Daheron L., Loring J.F., Haggarty S.J. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One 2011, 6:e26203.
115. Shi P., Scott M.A., Ghosh B., Wan D., Wissner-Gross Z., Mazitschek R., Haggarty S.J., Yanik M.F. Synapse microarray identification of small molecules that enhance synaptogenesis. Nat Commun 2011, 2:510.
116. Sklar P., Ripke S., Scott L.J., Andreassen O.A., Cichon S., Craddock N., Edenberg H.J., Nurnberger J.I., Rietschel M., Blackwood D., Corvin A., Flickinger M., Guan W., Mattingsdal M., McQuillin A., Kwan P., Wienker T.F., Daly M., Dudbridge F., Holmans P.A., Lin D., Burmeister M., Greenwood T.A., Hamshere M.L., Muglia P., Smith E.N., Zandi P.P., Nievergelt C.M., McKinney R., Shilling P.D., Schork N.J., Bloss C.S., Foroud T., Koller D.L., Gershon E.S., Liu C., Badner J.A., Scheftner W.A., Lawson W.B., Nwulia E.A., Hipolito M., Coryell W., Rice J., Byerley W., McMahon F.J., Schulze T.G., Berrettini W., Lohoff F.W., Potash J.B., Mahon P.B., McInnis M.G., Zollner S., Zhang P., Craig D.W., Szelinger S., Barrett T.B., Breuer R., Meier S., Strohmaier J., Witt S.H., Tozzi F., Farmer A., McGuffin P., Strauss J., Xu W., Kennedy J.L., Vincent J.B., Matthews K., Day R., Ferreira M.A., O'Dushlaine C., Perlis R., Raychaudhuri S., Ruderfer D., Hyoun P.L., Smoller J.W., Li J., Absher D., Thompson R.C., Meng F.G., Schatzberg A.F., Bunney W.E., Barchas J.D., Jones E.G., Watson S.J., Myers R.M., Akil H., Boehnke M., Chambert K., Moran J., Scolnick E., Djurovic S., Melle I., Morken G., Gill M., Morris D., Quinn E., Muhleisen T.W., Degenhardt F.A., Mattheisen M., Schumacher J., Maier W., Steffens M., Propping P., Nothen M.M., Anjorin A., Bass N., Gurling H., Kandaswamy R., Lawrence J., McGhee K., McIntosh A., McLean A.W., Muir W.J., Pickard B.S., Breen G., St Clair D., Caesar S., Gordon-Smith K., Jones L., Fraser C., Green E.K., Grozeva D., Jones I.R., Kirov G., Moskvina V., Nikolov I., O'Donovan M.C., Owen M.J., Collier D.A., Elkin A., Williamson R., Young A.H., Ferrier I.N., Stefansson K., Stefansson H., Thornorgeirsson T., Steinberg S., Gustafsson O., Bergen S.E., Nimgaonkar V., Hultman C., Landen M., Lichtenstein P., Sullivan P., Schalling M., Osby U., Backlund L., Frisen L., Langstrom N., Jamain S., Leboyer M., Etain B., Bellivier F., Petursson H., Sigur Sson E., Muller-Mysok B., Lucae S., Schwarz M., Schofield P.R., Martin N., Montgomery G.W., Lathrop M., Oskarsson H., Bauer M., Wright A., Mitchell P.B., Hautzinger M., Reif A., Kelsoe J.R., Purcell S.M. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011, 43:977-983.
117. Su I.H., Dobenecker M.W., Dickinson E., Oser M., Basavaraj A., Marqueron R., Viale A., Reinberg D., Wulfing C., Tarakhovsky A. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 2005, 121:425-436.
118. Sun H., Kennedy P.J., Nestler E.J. Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology 2012, 38:124-137.
119. Thase M.E., Macfadden W., Weisler R.H., Chang W., Paulsson B., Khan A., Calabrese J.R. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006, 26:600-609.
120. Tohen M., Hennen J., Zarate C.M., Baldessarini R.J., Strakowski S.M., Stoll A.L., Faedda G.L., Suppes T., Gebre-Medhin P., Cohen B.M. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000, 157:220-228.
121. Tohen M., Zarate C.A., Hennen J., Khalsa H.M., Strakowski S.M., Gebre-Medhin P., Salvatore P., Baldessarini R.J. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003, 160:2099-2107.
122. Tremolizzo L., Carboni G., Ruzicka W.B., Mitchell C.P., Sugaya I., Tueting P., Sharma R., Grayson D.R., Costa E., Guidotti A. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci U S A 2002, 99:17095-17100.
123. Tremolizzo L., Doueiri M.S., Dong E., Grayson D.R., Davis J., Pinna G., Tueting P., Rodriguez-Menendez V., Costa E., Guidotti A. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry 2005, 57:500-509.
124. Tsai M.C., Manor O., Wan Y., Mosammaparast N., Wang J.K., Lan F., Shi Y., Segal E., Chang H.Y. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010, 329:689-693.
125. Tsankova N., Renthal W., Kumar A., Nestler E.J. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007, 8:355-367.
126. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9:519-525.
127. Tsankova N.M., Kumar A., Nestler E.J. Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. J Neurosci 2004, 24:5603-5610.
128. Uchida S., Hara K., Kobayashi A., Otsuki K., Yamagata H., Hobara T., Suzuki T., Miyata N., Watanabe Y. Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron 2011, 69:359-372.
129. Vecsey C.G., Hawk J.D., Lattal K.M., Stein J.M., Fabian S.A., Attner M.A., Cabrera S.M., McDonough C.B., Brindle P.K., Abel T., Wood M.A. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci 2007, 27:6128-6140.
130. Verdin E., Dequiedt F., Kasler H.G. Class II histone deacetylases: versatile regulators. Trends Genet 2003, 19:286-293.
131. Vieta E., Calabrese J.R., Goikolea J.M., Raines S., Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007, 9:413-425.
132. Weaver I.C., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.R., Dymov S., Szyf M., Meaney M.J. Epigenetic programming by maternal behavior. Nat Neurosci 2004, 7:847-854.
133. Weisler R.H., Calabrese J.R., Thase M.E., Arvekvist R., Stening G., Paulsson B., Suppes T. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008, 69:769-782.
134. Wilkinson M.B., Xiao G., Kumar A., LaPlant Q., Renthal W., Sikder D., Kodadek T.J., Nestler E.J. Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models. J Neurosci 2009, 29:7820-7832.
135. Wood M.A., Kaplan M.P., Park A., Blanchard E.J., Oliveira A.M., Lombardi T.L., Abel T. Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn Membr 2005, 12:111-119.
136. World Health Organization (2004) The global burden of disease: 2004 update. http://www.who.int/entity/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.
137. Yamawaki Y., Fuchikami M., Morinobu S., Segawa M., Matsumoto T., Yamawaki S. Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus. World J Biol Psychiatry 2012, 13:458-467.
138. Yang N., Ng Y.H., Pang Z.P., Sudhof T.C., Wernig M. Induced neuronal cells: how to make and define a neuron. Cell Stem Cell 2011, 9:517-525.
139. Zarate C., Machado-Vieira R., Henter I., Ibrahim L., Diazgranados N., Salvadore G. Glutamatergic modulators: the future of treating mood disorders?. Harv Rev Psychiatry 2010, 18:293-303.
140. Zarate C.A., Tohen M., Land M., Cavanagh S. Functional impairment and cognition in bipolar disorder. Psychiatry Q 2000, 71:309-329.
141. Zibetti C., Adamo A., Binda C., Forneris F., Toffolo E., Verpelli C., Ginelli E., Mattevi A., Sala C., Battaglioli E. Alternative splicing of the histone demethylase LSD1/KDM1 contributes to the modulation of neurite morphogenesis in the mammalian nervous system. J Neurosci 2010, 30:2521-2532.
142. Zimmermann N., Zschocke J., Perisic T., Yu S., Holsboer F., Rein T. Antidepressants inhibit DNA methyltransferase 1 through reducing G9a levels. Biochem J 2012, 448:93-102.